This webinar presented by Duncan Curley will provide an update on the recent caselaw on SPCs: the end of the Truvada (Gilead v Teva and others) saga; the CJEU decisions of 2019 reviewed; discussion of the latest references; some thoughts on the SPC manufacturing waiver and finally, some speculation about what the future holds for SPCs in the UK, having “taken back control”.
Dr Duncan Curley qualified as a solicitor in 1995. He subsequently became a partner in the intellectual property department of an international law firm. He founded the boutique IP legal practice, Innovate Legal, in 2007. The firm acts for multinational and UK-based generic pharmaceutical companies on patent and trademark issues, including freedom to operate, patent clearance and litigation. Duncan is the author of numerous published articles on IP issues and a study entitled “Extending Rewards for Innovative Drug Development”, a Report on Supplementary Protection Certificates that was published by the Intellectual Property Institute in 2007.